Are Peptides Legal? How U.S. Law Treats Each Type of Peptide

Are peptides legal? In the United States the answer depends on which peptide it is and how it reaches you. FDA-approved peptide drugs such as insulin and semaglutide are legal with a prescription. Collagen peptides sold as dietary supplements are legal to sell over the counter. Compounded peptides are legal only when the pharmacy follows strict federal rules, and peptides sold as “research use only” are not legal to market for human use. This guide explains each category, including the 2026 changes to how the FDA treats peptides in compounding.

Peptide Labs sells dietary supplements, including collagen peptides, but does not sell any prescription, investigational or unapproved peptide. This article is general information, not legal or medical advice.

What counts as a peptide under U.S. law?

A peptide is a short chain of amino acids. Since March 2020 the FDA has defined a protein as a chain of more than 40 amino acids, so anything with 40 or fewer counts as a peptide. The line matters for which approval pathway applies: insulin, with 51 amino acids across two chains, is now regulated as a biologic, while semaglutide and tirzepatide are approved as drugs. (See what peptides are for the science.)

Legally, the more important question is what the product is: an approved medicine, a compounded preparation, an unapproved drug, or a food or dietary supplement.

Are peptides legal? The four ways they are sold in the U.S.

FDA-approved peptides

Dozens of FDA-approved peptides are in everyday use. Besides insulin and the GLP-1 medicines (semaglutide, tirzepatide and liraglutide), examples include oxytocin, octreotide, leuprolide, tesamorelin (Egrifta), bremelanotide (Vyleesi) and afamelanotide (Scenesse).

Two limits apply. First, the approval covers the specific approved product, not every vial sold under the same chemical name. Second, these are prescription drugs: dispensing them without a valid prescription is illegal. Our article on what “FDA-approved prescription drug” means covers this in more detail.

Compounded peptides: 503A, 503B and the bulks categories

Compounding is when a pharmacist prepares a medicine for a patient, for example in a different strength or without an ingredient the patient is allergic to. Federal law recognizes two kinds of compounders. 503A pharmacies are state-licensed pharmacies that compound for individual patients with a prescription. 503B outsourcing facilities register with the FDA, follow manufacturing-quality standards and can make larger batches.

Compounded drugs are not FDA-approved, and a 503A pharmacy cannot use just any raw ingredient. A bulk drug substance generally has to meet one of three conditions: it has a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the FDA’s “503A bulks list.” While the FDA evaluates nominated substances, it sorts them into interim categories:

• Category 1: under evaluation, with no significant safety concerns identified so far. The FDA generally does not object to compounding with these while it decides.
• Category 2: substances that raise significant safety risks. The FDA has said pharmacies should not compound with them.
• Category 3: nominated without enough supporting information.

A substance in none of these groups, and not otherwise eligible, is not a lawful ingredient for 503A compounding.

2025-2026: what changed for peptide compounding

Peptides became a flashpoint after the FDA placed a number of popular ones, including BPC-157, in Category 2 in 2023, citing risks such as immune reactions and peptide-related impurities. The timeline since then:

• Late February 2026: Health and Human Services Secretary Robert F. Kennedy Jr. said publicly that he expected FDA action to make about 14 peptides more accessible through compounding.
• April 15, 2026: the FDA announced that 12 peptides would leave Category 2 because their nominators had withdrawn the nominations: BPC-157, LL-37, dihexa, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, pegylated mechano growth factor, melanotan II, MOTS-c, Semax and TB-500. The FDA stated that removal does not make these substances eligible for 503A compounding.
• July 23-24, 2026: the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list. It narrowly voted to recommend six (BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax) and voted against emideltide. The BPC-157 vote was 8 to 6 with one abstention. FDA scientific staff had recommended against all seven, citing limited clinical data.
• As of late September 2026: the FDA has not added any of these peptides to the 503A bulks list. Committee votes are non-binding, and adding a substance normally requires notice-and-comment rulemaking. The FDA’s May 2026 list still places kisspeptin-10 in Category 2.

Some articles written before April 2026 still describe a longer Category 2 list; check the date of anything you read. For the profiles of these compounds, see BPC-157, TB-500, MOTS-c, Semax, epitalon, KPV and kisspeptin-10. None of them is FDA-approved.

Research peptides and "research use only" labels

“Research peptides” is the industry name for peptides sold online as laboratory chemicals, often with the disclaimer “not for human consumption.” Selling a chemical to a genuine laboratory is one thing. Selling vials with dosing charts, weight-loss claims and syringes is another, and the FDA looks at the whole picture, not just the label.

In 2026 the FDA issued warning letters to online sellers of research-labeled semaglutide, tirzepatide and retatrutide, including letters dated March 31 and August 24. In each case the agency said evidence on the seller’s website established that the products were intended as drugs for human use, making them unapproved new drugs. Investigational peptides such as retatrutide cannot legally be sold for human use at all outside an authorized clinical trial.

Peptide supplements: collagen and food-derived peptides

Collagen peptides are made by breaking down collagen protein from sources such as cattle hides or fish skin. They are sold as foods and dietary supplements, which are legal to sell without a prescription. Supplements do not need FDA approval before sale, but manufacturers must follow manufacturing and labeling rules and cannot claim that a supplement treats or cures a disease. Our collagen peptides buying guide explains what to look for on the label.

A peptide that is being studied or sold as a drug cannot simply be relabeled as a supplement, and the word “peptide” on a supplement does not mean it acts like a peptide drug.

What "peptide therapy" usually means

“Peptide therapy” is a marketing term, not a medical specialty. Wellness, anti-aging and sports clinics use it for anything from FDA-approved GLP-1 prescriptions to compounded injections of peptides that have never been approved. The legal status depends entirely on what is in the syringe. Reasonable questions to ask any provider:

1. Is this an FDA-approved product, and is it approved for the reason I would be using it?
2. If it is compounded, which licensed pharmacy makes it, and is the ingredient eligible for compounding?
3. What human clinical evidence exists, and what are the known risks?
4. Will a licensed prescriber review my medical history and follow up with me?

At least one state has acted directly: the Ohio Board of Pharmacy has taken enforcement action against clinics and distributors over peptides including BPC-157, AOD-9604 and ipamorelin. States license pharmacies, prescribers and clinics, so state rules can be stricter than federal ones.

Peptides in competitive sport

Athletes subject to anti-doping rules face a separate test. The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 as a non-approved substance banned at all times. It also bans growth hormone fragments such as AOD-9604, GHRH analogs such as CJC-1295, sermorelin and tesamorelin, growth hormone secretagogues such as ipamorelin, and thymosin beta-4 derivatives such as TB-500. Semaglutide and tirzepatide are not prohibited, but both are on WADA’s 2026 monitoring program.

Frequently Asked Questions

Last reviewed September 2026. Peptide regulation is changing quickly; check the FDA’s current compounding lists and your state’s rules before relying on any summary. These statements are general information and are not legal or medical advice.